Article

Nintedanib inhibits the VEGFR-ERK signaling pathway in human KRAS-mutated cancer cells

2025-12-18

Abstract excerpt

<title>Abstract</title> <p>KRAS mutations are significant drivers in various cancers, and existing drug discovery efforts targeting these mutations have largely been unsuccessful, highlighting the need for more effective therapies. In this study, screening library, which contains 1374 chemical compounds, identified Nintedanib, a VEGFR inhibitor, as having a potent and selective antiproliferative effect against KR...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 33e2c752-1462-514a-81c9-c8753129c5e1
DOI: 10.21203/rs.3.rs-8370175/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Nintedanib inhibits the VEGFR-ERK signaling pathway in human KRAS-mutated cancer cellsDOI 10.21203/rs.3.rs-8370175/v1Read

The KRASG12D Inhibitor Pipeline Grows.Semantic proximity Read

VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activationSemantic proximity Read

Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer typesSemantic proximity Read

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trialsSemantic proximity Read

Discovery of novel indazole derivatives as SOS1 agonists that activate KRAS signaling.Semantic proximity Read

ERK-dependent protein phosphorylation in KRAS-mutant cancer: a mix of the expected and surprising.Semantic proximity Read

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAFi/ErbB1 inhibitorsSemantic proximity Read

Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis-New insight and futuristic vision.Semantic proximity Read

Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancerSemantic proximity Read

ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERKSemantic proximity Read

Developing SHP2-based combination therapy for KRAS-amplified cancer.Semantic proximity Read

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.Semantic proximity Read